Compare BIO-TECHNE Corp (TECH) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Short Term Corporate Bond ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Vanguard Short Term Corporate Bond ETF trades at $78.09. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Short Term Corporate Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VCSH | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Fixed Income |
52-Week High | $72.48 | $80.20 |
52-Week Low | $43.31 | $78.08 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.14 with minimal daily movement (-0.05%). The technical picture is bearish with moving averages signaling caution, though oversold RSI readings suggest potential near-term support. The ETF maintains a competitive 4.5% dividend yield with a short 2.7-year duration, positioning it defensively against rising rates while offering higher income than treasury alternatives.
While VCSH provides quality short-term corporate bond exposure with minimal interest rate risk, current tight credit spreads limit upside potential. The ETF faces competition from broader bond funds and carries corporate credit risk. Recent analyst downgrades to 'Hold' reflect concerns about entry timing, though institutional investors continue active positioning in the fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
